AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22796997 — intervention group
Group type: EXPERIMENTAL
Intervention: H60
Number of subjects: 6
Study 22796997 — intervention group
Group type: EXPERIMENTAL
Intervention: H90
Number of subjects: 6
Study 22796997 — intervention group
Group type: EXPERIMENTAL
Intervention: S60
Number of subjects: 6
Study 22796997 — intervention group
Group type: EXPERIMENTAL
Intervention: S90
Number of subjects: 6
Study 22796997 — intervention group
Group type: EXPERIMENTAL
Intervention: All protocols
Number of subjects: 6
Study 20609719 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal (TEP) procedure
Number of subjects: 64
Study 20609719 — intervention group
Group type: COMPARATOR
Intervention: Stoppa procedure
Number of subjects: 64
Study 17671280 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1816
Study 17671280 — intervention group
Group type: EXPERIMENTAL
Intervention: GRIK4 gene marker (rs1954787)
Number of subjects: 1816
Study 17671280 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR2A gene marker
Number of subjects: 1816
Study 16224673 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Halo-traction
Number of subjects: 25
Study 16224673 — intervention group
Group type: COMPARATOR
Intervention: Direct operative correction and instrumentation (no Halo-traction)
Number of subjects: 25
Study 14605997 — intervention group
Group type: COMPARATOR
Intervention: Bolus rGLP-1 injections at 1.5 nmol/kg
Number of subjects: 40
Study 14605997 — intervention group
Group type: COMPARATOR
Intervention: Continuous rGLP-1 infusion at up to 4.5 pmol/kg/min
Number of subjects: 40
Study 14605997 — intervention group
Group type: COMPARATOR
Intervention: Continuous rGLP-1 infusion in SU cohort
Number of subjects: 40
Study 14605997 — intervention group
Group type: EXPERIMENTAL
Intervention: rGLP-1 infusions
Number of subjects: 40
Study 10584647 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily heparin flushes with once-weekly urokinase instillation (group B, n = 53)
Number of subjects: 105
Study 10584647 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily heparin flushes (group A, n = 52)
Number of subjects: 105
Study 8911112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 25 mg
Number of subjects: 399
Study 8911112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 50 mg
Number of subjects: 399
Study 8911112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 100 mg
Number of subjects: 399
Study 8911112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 200 mg
Number of subjects: 399
Study 8911112 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg x 3 or 8 mg x 4)
Number of subjects: 399
Study 8911112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate and Ondansetron
Number of subjects: 399
Study 1868444 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (BAY g 5421)
Number of subjects: 12
Study 1868444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6135820 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 0
Study 6135820 — intervention group
Group type: COMPARATOR
Intervention: Timolol (Control)
Number of subjects: 0
Study 3010510 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin
Number of subjects: 49
Study 3010510 — intervention group
Group type: COMPARATOR
Intervention: Control immune globulin
Number of subjects: 49
Study 31179773 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mucoadhesive film containing chitosan
Number of subjects: 72
Study 31179773 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 29584492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle helmets tested at 3.4 m/s
Number of subjects: 10
Study 29584492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle helmets tested at 6.2 m/s
Number of subjects: 10
Study 27912735 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb measles vaccine at 4.5 and 9 months (group A)
Number of subjects: 6648
Study 27912735 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb measles vaccine at 4.5 months (group A)
Number of subjects: 6648
Study 27912735 — intervention group
Group type: COMPARATOR
Intervention: No vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B)
Number of subjects: 6648
Study 27912735 — intervention group
Group type: COMPARATOR
Intervention: No vaccine at 4.5 months and Schwarz measles vaccine at 9 months (group C)
Number of subjects: 6648
Study 24636340 — intervention group
Group type: EXPERIMENTAL
Intervention: Before-contouring era (BC)
Number of subjects: 140
Study 24636340 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-contouring era (PC)
Number of subjects: 140
Study 24636340 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary chain (IMC) treated
Number of subjects: 140
Study 24636340 — intervention group
Group type: COMPARATOR
Intervention: Conservation vs Mastectomy
Number of subjects: 140
Study 24636340 — intervention group
Group type: COMPARATOR
Intervention: Boost vs No Boost
Number of subjects: 140
Study 24040472 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively-charged aerosol therapy (2 hours per time, twice a day)
Number of subjects: 140
Study 24040472 — intervention group
Group type: COMPARATOR
Intervention: Normal, routine treatment
Number of subjects: 140
Study 20942277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion therapy of excitation‐focus transfer
Number of subjects: 80
Study 20942277 — intervention group
Group type: COMPARATOR
Intervention: Routine medications
Number of subjects: 80
Study 18560130 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 1826
Study 18560130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1826
Study 16809801 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ritonavir 100 mg
Number of subjects: 16
Study 16809801 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lopinavir/ritonavir 400/100 mg
Number of subjects: 16
Study 16809801 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state lopinavir/ritonavir 400/100 mg twice daily
Number of subjects: 16
Study 16809801 — intervention group
Group type: COMPARATOR
Intervention: Control (fexofenadine 120 mg alone)
Number of subjects: 16
Study 11501455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 0
Study 11501455 — intervention group
Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 0
Study 11501455 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN biopsy followed by backup axillary dissection
Number of subjects: 0
Study 11501455 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN biopsy
Number of subjects: 0
Study 9931866 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive and endoscopic saphenous vein harvesting
Number of subjects: 55
Study 9931866 — intervention group
Group type: COMPARATOR
Intervention: Conventional saphenous vein harvesting
Number of subjects: 55
Study 7983661 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam
Number of subjects: 307
Study 7983661 — intervention group
Group type: COMPARATOR
Intervention: 500-1000 mg naproxen
Number of subjects: 307
Study 7983661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tenoxicam and naproxen
Number of subjects: 307
Study 2691478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 100 mg/kg/d in four divided iv doses for 14 days
Number of subjects: 20
Study 2691478 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 100 mg/kg/d in four divided iv doses for seven days, then oral 50 mg/kg/d for seven days
Number of subjects: 20
Study 51284 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 75
Study 51284 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled betamethasone valerate
Number of subjects: 75
Study 51284 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 75
Study 31838180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lindioil ointment
Number of subjects: 48
Study 31838180 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 48
Study 30018165 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention supporting activities to improve penicillin delivery, aligned with the chronic care model, with continuous quality-improvement feedback on adherence.
Number of subjects: 304
Study 30018165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 304
Study 27333534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling with 0.25 mm diameter needles (group A)
Number of subjects: 48
Study 27333534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling with 0.5 mm diameter needles (group B)
Number of subjects: 48
Study 27333534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling with 0.9 mm diameter needles (group C)
Number of subjects: 48
Study 27333534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling with varying needle diameters (0.25, 0.5, and 0.9 mm)
Number of subjects: 48
Study 25055716 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrine cleaning intervention
Number of subjects: 17564
Study 25055716 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 17564
Study 25055716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no latrine cleaning intervention)
Number of subjects: 17564
Study 23327021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.2 mg/kg)
Number of subjects: 105
Study 23327021 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen codeine (20 mg/kg)
Number of subjects: 105
Study 23327021 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and intravenous)
Number of subjects: 105
Study 23327021 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (dexamethasone, acetaminophen codeine, placebo)
Number of subjects: 105
Study 20478320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task of subtracting backwards by seven
Number of subjects: 0
Study 20478320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task of generating words of the same first letter
Number of subjects: 0
Study 20478320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low visuospatial processing load (eyes closed)
Number of subjects: 0
Study 20478320 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal visuospatial processing load (eyes open)
Number of subjects: 0
Study 20478320 — intervention group
Group type: EXPERIMENTAL
Intervention: High visuospatial processing load (eyes open, sway-referenced surround)
Number of subjects: 0
Study 18760982 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (self-monitoring and forming specific action plans for walking)
Number of subjects: 75
Study 18760982 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-monitoring daily pedometer-determined step count)
Number of subjects: 75
Study 18760982 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 75
Study 16320096 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogue tasks (empty time and time listening to an audiobook)
Number of subjects: 148
Study 16320096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep setting (nocturnal sleep and awake times)
Number of subjects: 148
Study 16320096 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-to-night wake time variability
Number of subjects: 148
Study 16320096 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological adjustment
Number of subjects: 148
Study 12585579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee prosthesis
Number of subjects: 2
Study 12585579 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing total knee prosthesis
Number of subjects: 2
Study 10190881 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hypoxic breathing at low altitude
Number of subjects: 15
Study 10190881 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude exposure (4559 m)
Number of subjects: 15
Study 10190881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic nerve activity
Number of subjects: 15
Study 7762844 — intervention group
Group type: EXPERIMENTAL
Intervention: IA bupivacaine
Number of subjects: 4
Study 7762844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac and IA bupivacaine
Number of subjects: 4
Study 7762844 — intervention group
Group type: EXPERIMENTAL
Intervention: IA bupivacaine with ketorolac
Number of subjects: 4
Study 7762844 — intervention group
Group type: EXPERIMENTAL
Intervention: IA ketorolac
Number of subjects: 4
Study 2111093 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 150
Study 2111093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 150
Study 2111093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 150
Study 637709 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (25 gm initially, then 150 gm/day for 3-5 days)
Number of subjects: 52
Study 637709 — intervention group
Group type: COMPARATOR
Intervention: No albumin (Control group)
Number of subjects: 52
Study 637709 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 52
Study 31637603 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic proctectomy (RP)
Number of subjects: 8107
Study 29998336 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate monitoring with a home-based wearable ECG patch
Number of subjects: 2659
Study 29998336 — intervention group
Group type: COMPARATOR
Intervention: Delayed monitoring with a home-based wearable ECG patch
Number of subjects: 2659
Study 29998336 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined actively monitored groups
Number of subjects: 2659
Study 29998336 — intervention group
Group type: COMPARATOR
Intervention: Matched observational controls
Number of subjects: 2659
Study 29998336 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 2659
Study 27684308 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin/metformin
Number of subjects: 245
Study 27684308 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin
Number of subjects: 245
Study 24608948 — intervention group
Group type: EXPERIMENTAL
Intervention: Grain sorghum muffin
Number of subjects: 10
Study 24608948 — intervention group
Group type: COMPARATOR
Intervention: Whole-wheat flour muffin (control)
Number of subjects: 10
Study 22263674 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg + fenofibric acid 135 mg
Number of subjects: 261
Study 22263674 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg + fenofibric acid 135 mg
Number of subjects: 261
Study 22166525 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) 30 mg/30 ml, 29 doses over 24 months
Number of subjects: 189
Study 22166525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirarubicin (THP) 30 mg/30 ml, 29 doses over 24 months
Number of subjects: 189
Study 22166525 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycamptothecin (HCPT) 30 mg/30 ml, 29 doses over 24 months
Number of subjects: 189
Study 22166525 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI and THP
Number of subjects: 189
Study 17635177 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 144
Study 17635177 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 144
Study 17635177 — intervention group
Group type: COMPARATOR
Intervention: Control group (92 controls from transversal study)
Number of subjects: 144
Study 16135725 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (40 mg)
Number of subjects: 10
Study 16135725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12404696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 62
Study 12404696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10645355 — intervention group
Group type: EXPERIMENTAL
Intervention: Early non-weightbearing ankle mobilisation
Number of subjects: 52
Study 10645355 — intervention group
Group type: COMPARATOR
Intervention: Ankle immobilisation
Number of subjects: 52
Study 7593479 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine and scopolamine
Number of subjects: 11
Study 7593479 — intervention group
Group type: EXPERIMENTAL
Intervention: behavioral activation
Number of subjects: 11
Study 7593479 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine
Number of subjects: 11
Study 7593479 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 7593479 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 11
Study 1951336 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 13
Study 1951336 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 13
Study 1951336 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 13
Study 7318625 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared coagulation
Number of subjects: 0
Study 31493397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 50 mg
Number of subjects: 249
Study 31493397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg
Number of subjects: 249
Study 31493397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 600 mg
Number of subjects: 249
Study 31493397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 31493397 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous mirikizumab 200 mg every 4 weeks
Number of subjects: 249
Study 31493397 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous mirikizumab 200 mg every 12 weeks
Number of subjects: 249
Study 28974849 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia (Group S)
Number of subjects: 120
Study 28974849 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (Group E)
Number of subjects: 120
Study 26084944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens treatment
Number of subjects: 104
Study 26084944 — intervention group
Group type: COMPARATOR
Intervention: Contact lens treatment
Number of subjects: 104
Study 24314875 — intervention group
Group type: EXPERIMENTAL
Intervention: RESMENA diet
Number of subjects: 55
Study 24314875 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 55
Study 24314875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 55
Study 21955403 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/day plus rosiglitazone 4 mg/day
Number of subjects: 53
Study 21955403 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 40 mg/day plus placebo
Number of subjects: 53
Study 19508722 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 29
Study 19508722 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA
Number of subjects: 29
Study 19508722 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA and clopidogrel combined
Number of subjects: 29
Study 17125998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.75 microg/mL with bupivacaine
Number of subjects: 171
Study 17125998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.75 microg/mL with ropivacaine
Number of subjects: 171
Study 17125998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.75 microg/mL with levobupivacaine
Number of subjects: 171
Study 17125998 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 171
Study 17125998 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 171
Study 17125998 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine alone
Number of subjects: 171
Study 15894238 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-carried cardiac ultrasound (HCU)
Number of subjects: 150
Study 15894238 — intervention group
Group type: COMPARATOR
Intervention: Full-featured standard echo (FE) system
Number of subjects: 150
Study 12243634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 682
Study 12243634 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia
Number of subjects: 682
Study 12243634 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer-type dementia
Number of subjects: 682
Study 9797234 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (0.5 g four times a day)
Number of subjects: 371
Study 9797234 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (4.5 g three times a day)
Number of subjects: 371
Study 8457237 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate (MPA) 0.01%, 0.05%, 0.1%, 0.5% ointment
Number of subjects: 165
Study 8457237 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate (MPA) 0.1% (cream, ointment, fatty ointment)
Number of subjects: 165
Study 8457237 — intervention group
Group type: COMPARATOR
Intervention: Difluocortolone 21-valerate 0.1% (DFV) ointment
Number of subjects: 165
Study 8457237 — intervention group
Group type: COMPARATOR
Intervention: Various corticosteroids (betamethasone 17,21-dipropionate 0.64%, betamethasone 17-valerate 0.1%, clobetasol 17-propionate 0.05%, hydrocortisone 17-butyrate 0.1%, prednicarbate 0.25%)
Number of subjects: 165
Study 3784450 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-molecular hydroxyethyl starch
Number of subjects: 0
Study 3784450 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 0
Study 3784450 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline solution
Number of subjects: 0
Study 31372210 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode Laser (DL)
Number of subjects: 56
Study 31372210 — intervention group
Group type: COMPARATOR
Intervention: Conventional Endodontic Treatment (Endo)
Number of subjects: 56
Study 29901374 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal conjugated equine estrogen (CEE) cream 0.5 g once a week
Number of subjects: 40
Study 29901374 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40